Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
39 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Richter Gedeon Nyrt. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Richter Gedeon Nyrt. - Product Pipeline Review - 2014', provides an overview of the Richter Gedeon Nyrt.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Richter Gedeon Nyrt.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Richter Gedeon Nyrt. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Richter Gedeon Nyrt.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Richter Gedeon Nyrt.'s pipeline products Reasons to buy - Evaluate Richter Gedeon Nyrt.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Richter Gedeon Nyrt. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Richter Gedeon Nyrt.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Richter Gedeon Nyrt. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Richter Gedeon Nyrt. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Richter Gedeon Nyrt. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Richter Gedeon Nyrt. Snapshot 5 Richter Gedeon Nyrt. Overview 5 Key Information 5 Key Facts 5 Richter Gedeon Nyrt. - Research and Development Overview 6 Key Therapeutic Areas 6 Richter Gedeon Nyrt. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Richter Gedeon Nyrt. - Pipeline Products Glance 11 Richter Gedeon Nyrt. - Late Stage Pipeline Products 11 Filing rejected/Withdrawn Products/Combination Treatment Modalities 11 Phase III Products/Combination Treatment Modalities 12 Richter Gedeon Nyrt. - Clinical Stage Pipeline Products 13 Phase II Products/Combination Treatment Modalities 13 Phase I Products/Combination Treatment Modalities 14 Richter Gedeon Nyrt. - Early Stage Pipeline Products 15 Discovery Products/Combination Treatment Modalities 15 Richter Gedeon Nyrt. - Drug Profiles 16 cariprazine 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 pegfilgrastim 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 RGH-618 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 rituximab biosimilar 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 trastuzumab biosimilar 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Richter Gedeon Nyrt. - Pipeline Analysis 23 Richter Gedeon Nyrt. - Pipeline Products by Target 23 Richter Gedeon Nyrt. - Pipeline Products by Route of Administration 25 Richter Gedeon Nyrt. - Pipeline Products by Molecule Type 26 Richter Gedeon Nyrt. - Pipeline Products by Mechanism of Action 27 Richter Gedeon Nyrt. - Recent Pipeline Updates 29 Richter Gedeon Nyrt. - Dormant Projects 32 Richter Gedeon Nyrt. - Discontinued Pipeline Products 33 Discontinued Pipeline Product Profiles 33 radiprodil 33 RGH-512 33 Richter Gedeon Nyrt. - Company Statement 34 Richter Gedeon Nyrt. - Locations And Subsidiaries 35 Head Office 35 Other Locations & Subsidiaries 35 Appendix 38 Methodology 38 Coverage 38 Secondary Research 38 Primary Research 38 Expert Panel Validation 38 Contact Us 39 Disclaimer 39
List of Tables Richter Gedeon Nyrt., Key Information 5 Richter Gedeon Nyrt., Key Facts 5 Richter Gedeon Nyrt. - Pipeline by Indication, 2014 8 Richter Gedeon Nyrt. - Pipeline by Stage of Development, 2014 9 Richter Gedeon Nyrt. - Monotherapy Products in Pipeline, 2014 10 Richter Gedeon Nyrt. - Filing rejected/Withdrawn, 2014 11 Richter Gedeon Nyrt. - Phase III, 2014 12 Richter Gedeon Nyrt. - Phase II, 2014 13 Richter Gedeon Nyrt. - Phase I, 2014 14 Richter Gedeon Nyrt. - Discovery, 2014 15 Richter Gedeon Nyrt. - Pipeline by Target, 2014 24 Richter Gedeon Nyrt. - Pipeline by Route of Administration, 2014 25 Richter Gedeon Nyrt. - Pipeline by Molecule Type, 2014 26 Richter Gedeon Nyrt. - Pipeline Products by Mechanism of Action, 2014 28 Richter Gedeon Nyrt. - Recent Pipeline Updates, 2014 29 Richter Gedeon Nyrt. - Dormant Developmental Projects,2014 32 Richter Gedeon Nyrt. - Discontinued Pipeline Products, 2014 33 Richter Gedeon Nyrt., Other Locations 35 Richter Gedeon Nyrt., Subsidiaries 36
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.